Biological Function of EMMPRIN in Tumor Progression_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 YANGJing , LIHong-jiang ,  YANGXiao-qin

Department of Thyroid and Breast Surgery, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China;

Corresponding author：

YANGXiao-qin, Email: laurayang1977@hotmail.com

Keywords：

Extracellular matrix metalloproteinase inducer; Matrix metalloproteinases; Tumor progression; Cell apoptosis; Chemoresistance

DOI：

10.7507/1007-9424.20160230

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To summarize the biological function of extracellular matrix metalloproteinase inducer (EMMPRIN) in tumor progression, and its roles in clinical diagnosis and treatment in recent years. Methods Literatures about the recent studies on molecular structure of EMMPRIN and biological function in tumor progression were reviewed according to the results searched from PubMed database. Results EMMPRIN play important roles in the tumor progression, involved in inducing the degradation of extracellula matrix, promoting angiogenesis, inhibiting apoptosis, enhancing chemoresistance and so on. Conclusion EMMPRIN could be a potential therapeutic target in turmor.

Citation： YANGJing, LIHong-jiang, YANGXiao-qin. Biological Function of EMMPRIN in Tumor Progression. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2016, 23(7): 880-886. doi: 10.7507/1007-9424.20160230 Copy

1.	Kanyenda LJ, Verdile G, Boulos S, et al. The dynamics of CD147 in Alzheimer's disease development and pathology. J Alzheimers Dis, 2011, 26(4): 593-605.
2.	Guo H, Li R, Zucker S, et al. EMMPRIN (CD147), an inducer of matrix metalloproteinase synthesis, also binds interstitial collagenase to the tumor cell surface. Cancer Res, 2000, 60(4): 888-891.
3.	Seizer P, Ochmann C, Schonberger T, et al. Disrupting the EMMPRIN (CD147)-cyclophilin A interaction reduces infarct size and preserves systolic function after myocardial ischemia and reperfusion. Arterioscler Thromb Vasc Biol, 2011, 31(6): 1377-1386.
4.	Ozeki N, Kawai R, Hase N, et al. Alpha2 integrin, extracellular matrix metalloproteinase inducer, and matrix metalloproteinase-3 act sequentially to induce differentiation of mouse embryonic stem cells into odontoblast-like cells. Exp Cell Res, 2015, 331(1): 21-37.
5.	Ko MH, Puglielli L. The sterol carrier protein SCP-x/pro-SCP-2 gene has transcriptional activity and regulates the Alzheimer disease gamma-secretase. J Biol Chem, 2007, 282(27): 19742-19752.
6.	Du ZM, Hu CF, Shao Q, et al. Upregulation of caveolin-1 and CD147 expression in nasopharyngeal carcinoma enhanced tumor cell migration and correlated with poor prognosis of the patients. Int J Cancer, 2009, 125(8): 1832-1841.
7.	Crosnier C, Bustamante LY, Bartholdson SJ, et al. Basigin is a rece-ptor essential for erythrocyte invasion by plasmodium falciparum. Nature, 2011, 480(7378): 534-537.
8.	Zhu H, Zhao J, Zhu B, et al. EMMPRIN regulates cytoskeleton reorganization and cell adhesion in prostate cancer. Prostate, 2012, 72(1): 72-81.
9.	Fok KL, Chen H, Ruan YC, et al. Novel regulators of spermatogen-esis. Semin Cell Dev Biol, 2014, 29: 31-42.
10.	Lee CL, Lam MP, Lam KK, et al. Identification of CD147 (basigin) as a mediator of trophoblast functions. Hum Reprod, 2013, 28(11): 2920-2929.
11.	Hahn JN, Kaushik DK, Yong VW. The role of EMMPRIN in T cell biology and immunological diseases. J Leukoc Biol, 2015, 98(1): 33-48.
12.	Gabison EE, Huet E, Baudouin C, et al. Direct epithelial-stromal interaction in corneal wound healing: role of EMMPRIN/CD147 in MMPs induction and beyond. Prog Retin Eye Res, 2009, 28(1): 19-33.
13.	Nahalkova J, Volkmann I, Aoki M, et al. CD147, a gamma-secretase associated protein is upregulated in Alzheimer's disease brain and its cellular trafficking is affected by presenilin-2. Neurochem Int, 2010, 56(1): 67-76.
14.	Morita Y, Finger TE. Area postrema of the goldfish, Carassius aura-tus: ultrastructure, fiber connections, and immunocytochemistry. J Comp Neurol, 1987, 256(1): 104-116.
15.	Agrawal SM, Yong VW. The many faces of EMMPRIN-roles in neuroinflammation. Biochim Biophys Acta, 2011, 1812(2): 213-219.
16.	Menck K, Scharf C, Bleckmann A, et al. Tumor-derived microve-sicles mediate human breast cancer invasion through differentially glycosylated EMMPRIN. J Mol Cell Biol, 2015, 7(2): 143-153.
17.	Walters DK, Arendt BK, Jelinek DF. CD147 regulates the expression of MCT1 and lactate export in multiple myeloma cells. Cell Cycle, 2013, 12(19): 3175-3183.
18.	Yang JM, O'Neill P, Jin W, et al. Extracellular matrix metallopro-teinase inducer (CD147) confers resistance of breast cancer cells to Anoikis through inhibition of Bim. J Biol Chem, 2006, 281(14): 9719-9727.
19.	Wang B, Xu YF, He BS, et al. RNAi-mediated silencing of CD147 inhibits tumor cell proliferation, invasion and increases chemosensi-tivity to cisplatin in SGC7901 cells in vitro. J Exp Clin Cancer Res, 2010, 29: 61.
20.	Sato M, Nakai Y, Nakata W, et al. EMMPRIN promotes angiogenesis, proliferation, invasion and resistance to sunitinib in renal cell carcinoma, and its level predicts patient outcome. PLoS One, 2013, 8(9): e74313.
21.	Zhao S, Ma W, Zhang M, et al. High expression of CD147 and MMP-9 is correlated with poor prognosis of triple-negative breast cancer (TNBC) patients. Med Oncol, 2013, 30(1): 335.
22.	Liu Y, Xin T, Jiang QY, et al. CD147, MMP9 expression and clinical significance of basal-like breast cancer. Med Oncol, 2013, 30(1): 366.
23.	Li L, Tang W, Wu X, et al. HAb18G/CD147 promotes pSTAT3-mediated pancreatic cancer development via CD44s. Clin Cancer Res, 2013, 19(24): 6703-6715.
24.	Gabison EE, Hoang-Xuan T, Mauviel A, et al. EMMPRIN/CD147, an MMP modulator in cancer, development and tissue repair. Biochimie, 2005, 87(3-4): 361-368.
25.	Kaname T, Miyauchi T, Kuwano A, et al. Mapping basigin (BSG), a member of the immunoglobulin superfamily, to 19p13.3. Cytogenet Cell Genet, 1993, 64(3-4): 195-197.
26.	Xiong L, Edwards CK 3rd, Zhou L. The biological function and clinical utilization of CD147 in human diseases: a review of the current scientific literature. Int J Mol Sci, 2014, 15(10): 17411-17441.
27.	Khayati F, Perez-Cano L, Maouche K, et al. EMMPRIN/CD147 is a novel coreceptor of VEGFR-2 mediating its activation by VEGF. Oncotarget, 2015, 6(12): 9766-9780.
28.	Zhao Y, Chen S, Gou WF, et al. The role of EMMPRIN expression in ovarian epithelial carcinomas. Cell Cycle, 2013, 12(17): 2899-2913.
29.	Ge H, Yuan W, Liu J, et al. Functional relevance of protein glycosy-lation to the pro-inflammatory effects of extracellular matrix metallo-proteinase inducer (EMMPRIN) on monocytes/macrophages. PLoS One, 2015, 10(2): e0117463.
30.	王艺璇, 高云涛, 崔龙彪, 等.他莫昔芬对糖尿病大鼠心肌CD147糖基化与MMPs的影响.中国应用生理学杂志, 2015, 31(1): 1-5.
31.	Sun J, Hemler ME. Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions. Cancer Res, 2001, 61(5): 2276-2281.
32.	Nagashima S, Sakurai K, Suzuki S, et al. CD147 expression in non-invasive and invasive breast carcinoma. Gan To Kagaku Ryoho, 2014, 41(10): 1267-1269.
33.	Nakamura K, Kodama J, Hongo A, et al. Role of emmprin in endom--etrial cancer. BMC Cancer, 2012, 12: 191.
34.	Gao J, Hu Z, Liu J, et al. Expression of CD147 and Lewis y antigen in ovarian cancer and their relationship to drug resistance. Med Oncol, 2014, 31(5): 920.
35.	Liu DT. EMMPRIN in gynecologic cancers: pathologic and thera-peutic aspects. Tumour Biol, 2015, 36(7): 4883-4888.
36.	Sun X, Liu Y, Li M, et al. Involvement of miR-485-5p in hepatoce-llular carcinoma progression targeting EMMPRIN. Biomed Pharma-cother, 2015, 72: 58-65.
37.	Fei F, Li X, Xu L, et al. CD147-CD98hc complex contributes to poor prognosis of non-small cell lung cancer patients through promoting cell proliferation via the PI3K/Akt signaling pathway. Ann Surg Oncol, 2014, 21(13): 4359-4368.
38.	Chu D, Zhu S, Li J, et al. CD147 expression in human gastric cancer is associated with tumor recurrence and prognosis. PLoS One, 2014, 9(6): e101027.
39.	Abraham D, Zins K, Sioud M, et al. Host CD147 blockade by small interfering RNAs suppresses growth of human colon cancer xenografts. Front Biosci, 2008, 13: 5571-5579.
40.	Bilgin Doğru E, Dizdar Y, Aksit E, et al. EMMPRIN and ADAM12 in prostate cancer: preliminary results of a prospective study. Tumour Biol, 2014, 35(11): 11647-11653.
41.	程亮, 徐嘉雯, 何佳佳, 等.膀胱尿路上皮癌分子标记的临床应用进展.中华病理学杂志, 2011, 40(10): 714-717.
42.	Kim Y, Choi JW, Lee JH, et al. Expression of lactate/H+ symporters MCT1 and MCT4 and their chaperone CD147 predicts tumor progression in clear cell renal cell carcinoma: immunohistochemical and The Cancer Genome Atlas data analyses. Hum Pathol, 2015, 46(1): 104-112.
43.	万勇, 吴心愿.死亡相关蛋白激酶1和CD147在食管鳞癌中的表达及其临床意义.中华肿瘤杂志, 2012, 34(1): 44-48.
44.	Monteiro LS, Delgado ML, Ricardo S, et al. EMMPRIN expression in oral squamous cell carcinomas: correlation with tumor proliferation and patient survival. Biomed Res Int, 2014, 2014: 905680.
45.	Andrade AL, Ferreira SJ, Ferreira SM, et al. Immunoexpression of EGFR and EMMPRIN in a series of cases of head and neck squamous cell carcinoma. Pathol Res Pract. 2015, 211(10): 776-781.
46.	Yang M, Yuan Y, Zhang H, et al. Prognostic significance of CD147 in patients with glioblastoma. J Neurooncol, 2013, 115(1): 19-26.
47.	Hatanaka M, Higashi Y, Fukushige T, et al. Cleaved CD147 shed from the surface of malignant melanoma cells activates MMP2 produced by fibroblasts. Anticancer Res, 2014, 34(12): 7091-7096.
48.	Han YH, Gao B, Huang JH, et al. Expression of CD147, PCNA, VEGF, MMPs and their clinical significance in the giant cell tumor of bones. Int J Clin Exp Pathol, 2015, 8(7): 8446-8452.
49.	Urbaniak-Kujda D, Kapelko-Slowik K, Prajs I, et al. Increased expre-ssion of metalloproteinase-2 and-9 (MMP-2, MMP-9), tissue inhi-bitor of metalloproteinase-1 and-2 (TIMP-1, TIMP-2), and EMMPRIN (CD147) in multiple myeloma. Hematology, 2016, 21(1): 26-33.
50.	Li Y, Xu J, Chen L, et al. HAb18G (CD147), a cancer-associated biomarker and its role in cancer detection. Histopathology, 2009, 54(6): 677-687.
51.	Kang MJ, Kim HP, Lee KS, et al. Proteomic analysis reveals that CD147/EMMPRIN confers chemoresistance in cancer stem cell-like cells. Proteomics, 2013, 13(10-11): 1714-1725.
52.	Dai L, Guinea MC, Slomiany MG, et al. CD147-dependent hetero-geneity in malignant and chemoresistant properties of cancer cells. Am J Pathol, 2013, 182(2): 577-585.
53.	何慧婵, 韩兆冬, 戴奇山, 等.前列腺癌组织中CD147蛋白的表达及意义.中华医学杂志, 2009, 89(26): 1844-1846.
54.	Bhagirath D, Abrol N, Khan R, et al. Expression of CD147, BIGH3 and Stathmin and their potential role as diagnostic marker in patients with urothelial carcinoma of the bladder. Clin Chim Acta, 2012, 413(19-20): 1641-1646.
55.	Wu J, Hao ZW, Zhao YX, et al. Full-length soluble CD147 promotes MMP-2 expression and is a potential serological marker in detection of hepatocellular carcinoma. J Transl Med, 2014, 12: 190.
56.	Yu XL, Hu T, Du JM, et al. Crystal structure of HAb18G/CD147: implications for immunoglobulin superfamily homophilic adhesion. J Biol Chem, 2008, 283(26): 18056-18065.
57.	Cathcart J, Pulkoski-Gross A, Cao J. Targeting matrix metalloprotei-nases in cancer: bringing new life to old ideas. Genes Dis, 2015, 2(1): 26-34.
58.	涂燕, 李振江, 汤爱平, 等.干扰CD147表达对SHI-1细胞体内外增殖及浸润能力的影响及可能机制.中华血液学杂志, 2014, 35(8): 737-742.
59.	Taylor PM, Woodfield RJ, Hodgkin MN, et al. Breast cancer cell-derived EMMPRIN stimulates fibroblast MMP2 release through a phospholipase A(2) and 5-lipoxygenase catalyzed pathway. Oncogene, 2002, 21(37): 5765-5772.
60.	Chen Y, Gou X, Ke X, et al. Human tumor cells induce angiogenesis through positive feedback between CD147 and insulin-like growth factor-I. PLoS One, 2012, 7(7): e40965.
61.	Chen Y, Gou X, Kong DK, et al. EMMPRIN regulates tumor growth and metastasis by recruiting bone marrow-derived cells through paracrine signaling of SDF-1 and VEGF. Oncotarget, 2015, 6(32): 32575-32585.
62.	Wang H, Zhuo Y, Hu X, et al. CD147 deficiency blocks IL-8 secretion and inhibits lung cancer-induced osteoclastogenesis. Biochem Biophys Res Commun, 2015, 458(2): 268-273.
63.	Quemener C, Gabison EE, Naimi B, et al. Extracellular matrix meta-lloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion. Cancer Res, 2007, 67(1): 9-15.
64.	Slomiany MG, Grass GD, Robertson AD, et al. Hyaluronan, CD44, and emmprin regulate lactate efflux and membrane localization of monocarboxylate transporters in human breast carcinoma cells. Cancer Res, 2009, 69(4): 1293-301.
65.	Marchiq I, Le Floch R, Roux D, et al. Genetic disruption of lactate/H+ symporters (MCTs) and their subunit CD147/BASIGIN sensitizes glycolytic tumor cells to phenformin. Cancer Res, 2015, 75(1): 171-180.
66.	Deora AA, Philp N, Hu J, et al. Mechanisms regulating tissue-specific polarity of monocarboxylate transporters and their chaperone CD147 in kidney and retinal epithelia. Proc Natl Acad Sci U S A, 2005, 102 (45): 16245-16250.
67.	Su J, Chen X, Kanekura T. A CD147-targeting siRNA inhibits the proliferation, invasiveness, and VEGF production of human mali-gnant melanoma cells by down-regulating glycolysis. Cancer Lett, 2009, 273(1): 140-147.
68.	Gallagher SM, Castorino JJ, Wang D, et al. Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231. Cancer Res, 2007, 67(9): 4182-4189.
69.	周希, 吕洁玉, 龚宝兰.下调CD147通过Bcl-2途径诱导宫颈癌细胞SiHa细胞凋亡的研究.南方医科大学学报, 2010, 30(7): 1695-1698.
70.	Gao H, Jiang Q, Han Y, et al. shRNA-mediated EMMPRIN silencing inhibits human leukemic monocyte lymphoma U937 cell proliferation and increases chemosensitivity to adriamycin. Cell Biochem Biophys, 2015, 71(2): 827-835.
71.	Gou X, Ru Q, Zhang H, et al. HAb18G/CD147 inhibits starvation-induced autophagy in human hepatoma cell SMMC7721 with an involvement of Beclin 1 down-regulation. Cancer Sci, 2009, 100(5): 837-843.
72.	Kuang YH, Chen X, Su J, et al. RNA interference targeting the CD147 induces apoptosis of multi-drug resistant cancer cells related to XIAP depletion. Cancer Lett, 2009, 276(2): 189-195.
73.	Tang J, Guo YS, Zhang Y, et al. CD147 induces UPR to inhibit apoptosis and chemosensitivity by increasing the transcription of Bip in hepatocellular carcinoma. Cell Death Differ, 2012, 19(11): 1779-1790.
74.	李江伟, 李道明, 张岚, 等.沉默CD147基因对人甲状腺髓样癌TT细胞相关蛋白表达和生物学特性的影响.中华病理学杂志, 2014, 43(2): 103-108.
75.	Hao J, Madigan MC, Khatri A, et al. In vitro and in vivo prostate cancer metastasis and chemoresistance can be modulated by expression of either CD44 or CD147. PLoS One, 2012, 7(8): e40716.
76.	Ozler A, Evsen MS, Turgut A, et al. CD147 expression in uterine smooth muscle tumors, and its potential role as a diagnostic and prognostic marker in patients with leiomyosarcoma. J Exp Ther Oncol, 2014, 10(4): 325-330.
77.	Toole BP, Slomiany MG. Hyaluronan, CD44 and Emmprin: partners in cancer cell chemoresistance. Drug Resist Updat, 2008, 11(3): 110-121.
78.	Hao J, Chen H, Madigan MC, et al. Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression. Br J Cancer, 2010, 103(7): 1008-1018.
79.	胡芸, 吴宜林. CD147单克隆抗体对HCE1多细胞球体紫杉醇耐药的影响.中南大学学报医学版, 2011, 36(3): 192-202.
80.	Pan Y, He B, Song G, et al. CD147 silencing via RNA interference reduces tumor cell invasion, metastasis and increases chemosensiti-vity in pancreatic cancer cells. Oncol Rep, 2012, 27(6): 2003-2009.
81.	Zhou S, Liao L, Chen C, et al. CD147 mediates chemoresistance in breast cancer via ABCG2 by affecting its cellular localization and dimerization. Cancer Lett, 2013, 337(2): 285-292.
82.	Li QQ, Wang WJ, Xu JD, et al. Involvement of CD147 in regulation of multidrug resistance to P-gp substrate drugs and in vitro invasion in breast cancer cells. Cancer Sci, 2007, 98(7): 1064-1069.
83.	Zhu S, Chu D, Zhang Y, et al. EMMPRIN/CD147 expression is associated with disease-free survival of patients with colorectal cancer. Med Oncol, 2013, 30(1): 369.
84.	Boye K, Nesland JM, Sandstad B, et al. EMMPRIN is associated with S100A4 and predicts patient outcome in colorectal cancer. Br J Cancer, 2012, 107(4): 667-674.
85.	Xu Q, Ying M, Chen G, et al. ADAM17 is associated with EMMPRIN and predicts poor prognosis in patients with uterine cervical carci-noma. Tumour Biol, 2014, 35(8): 7575-7586.
86.	Choi JW, Kim Y, Lee JH, et al. Prognostic significance of lactate/proton symporters MCT1, MCT4, and their chaperone CD147 expressions in urothelial carcinoma of the bladder. Urology, 2014, 84(1): 245. e9-e15.
87.	Zhu S, Li Y, Mi L, et al. Clinical impact of HAb18G/CD147 expres-sion in esophageal squamous cell carcinoma. Dig Dis Sci, 2011, 56 (12): 3569-3576.
88.	Xu XY, Lin N, Li YM, et al. Expression of HAb18G/CD147 and its localization correlate with the progression and poor prognosis of non-small cell lung cancer. Pathol Res Pract, 2013, 209(6): 345-352.
89.	Rabien A, Stephan C, Kilic E, et al. Renal cell neoplasias: reversion-inducing cysteine-rich protein with Kazal motifs discriminates tumor subtypes, while extracellular matrix metalloproteinase inducer indicates prognosis. J Transl Med, 2013, 11: 258.
90.	Gou X, Chen H, Jin F, et al. Expressions of CD147, MMP-2 and MMP-9 in laryngeal carcinoma and its correlation with poor prognosis. Pathol Oncol Res, 2014, 20(2): 475-481.
91.	Futamura N, Nishida Y, Urakawa H, et al. EMMPRIN co-expressed with matrix metalloproteinases predicts poor prognosis in patients with osteosarcoma. Tumour Biol, 2014, 35(6): 5159-5165.
92.	Bi XC, Liu JM, He HC, et al. Extracellular matrix metalloproteinase inducer: a novel poor prognostic marker for human seminomas. Clin Transl Oncol, 2012, 14(3): 190-196.
93.	Zhong X, Li M, Nie B, et al. Overexpressions of RACK1 and CD147 associated with poor prognosis in stage T1 pulmonary adenocar-cinoma. Ann Surg Oncol, 2013, 20(3): 1044-1052.
94.	Sugyo A, Tsuji AB, Sudo H, et al. Evaluation of 89Zr-labeled human anti-CD147 monoclonal antibody as a positron emission tomography probe in a mouse model of pancreatic cancer. PLoS One, 2013, 8(4): e61230.
95.	Grupp K, Hohne TS, Prien K, et al. Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatec-tomy. Exp Mol Pathol, 2013, 95(2): 227-234.
96.	Bi XC, Liu JM, Zheng XG, et al. Over-expression of extracellular matrix metalloproteinase inducer in prostate cancer is associated with high risk of prostate-specific antigen relapse after radical prostatectomy. Clin Invest Med, 2011, 34(6): E358.
97.	Niu H, Wang R, Cheng J, et al. Treatment of 131I-labeled anti-CD147 monoclonal antibody in VX2 carcinoma-induced liver tumors. Oncol Rep, 2013, 30(1): 246-252.
98.	Bian H, Zheng JS, Nan G, et al. Randomized trial of 131I metuximab in treatment of hepatocellular carcinoma after percutaneous radio-frequency ablation. J Natl Cancer Inst, 2014, 106(9). pii: dju239.

1. Kanyenda LJ, Verdile G, Boulos S, et al. The dynamics of CD147 in Alzheimer's disease development and pathology. J Alzheimers Dis, 2011, 26(4): 593-605.
2. Guo H, Li R, Zucker S, et al. EMMPRIN (CD147), an inducer of matrix metalloproteinase synthesis, also binds interstitial collagenase to the tumor cell surface. Cancer Res, 2000, 60(4): 888-891.
3. Seizer P, Ochmann C, Schonberger T, et al. Disrupting the EMMPRIN (CD147)-cyclophilin A interaction reduces infarct size and preserves systolic function after myocardial ischemia and reperfusion. Arterioscler Thromb Vasc Biol, 2011, 31(6): 1377-1386.
4. Ozeki N, Kawai R, Hase N, et al. Alpha2 integrin, extracellular matrix metalloproteinase inducer, and matrix metalloproteinase-3 act sequentially to induce differentiation of mouse embryonic stem cells into odontoblast-like cells. Exp Cell Res, 2015, 331(1): 21-37.
5. Ko MH, Puglielli L. The sterol carrier protein SCP-x/pro-SCP-2 gene has transcriptional activity and regulates the Alzheimer disease gamma-secretase. J Biol Chem, 2007, 282(27): 19742-19752.
6. Du ZM, Hu CF, Shao Q, et al. Upregulation of caveolin-1 and CD147 expression in nasopharyngeal carcinoma enhanced tumor cell migration and correlated with poor prognosis of the patients. Int J Cancer, 2009, 125(8): 1832-1841.
7. Crosnier C, Bustamante LY, Bartholdson SJ, et al. Basigin is a rece-ptor essential for erythrocyte invasion by plasmodium falciparum. Nature, 2011, 480(7378): 534-537.
8. Zhu H, Zhao J, Zhu B, et al. EMMPRIN regulates cytoskeleton reorganization and cell adhesion in prostate cancer. Prostate, 2012, 72(1): 72-81.
9. Fok KL, Chen H, Ruan YC, et al. Novel regulators of spermatogen-esis. Semin Cell Dev Biol, 2014, 29: 31-42.
10. Lee CL, Lam MP, Lam KK, et al. Identification of CD147 (basigin) as a mediator of trophoblast functions. Hum Reprod, 2013, 28(11): 2920-2929.
11. Hahn JN, Kaushik DK, Yong VW. The role of EMMPRIN in T cell biology and immunological diseases. J Leukoc Biol, 2015, 98(1): 33-48.
12. Gabison EE, Huet E, Baudouin C, et al. Direct epithelial-stromal interaction in corneal wound healing: role of EMMPRIN/CD147 in MMPs induction and beyond. Prog Retin Eye Res, 2009, 28(1): 19-33.
13. Nahalkova J, Volkmann I, Aoki M, et al. CD147, a gamma-secretase associated protein is upregulated in Alzheimer's disease brain and its cellular trafficking is affected by presenilin-2. Neurochem Int, 2010, 56(1): 67-76.
14. Morita Y, Finger TE. Area postrema of the goldfish, Carassius aura-tus: ultrastructure, fiber connections, and immunocytochemistry. J Comp Neurol, 1987, 256(1): 104-116.
15. Agrawal SM, Yong VW. The many faces of EMMPRIN-roles in neuroinflammation. Biochim Biophys Acta, 2011, 1812(2): 213-219.
16. Menck K, Scharf C, Bleckmann A, et al. Tumor-derived microve-sicles mediate human breast cancer invasion through differentially glycosylated EMMPRIN. J Mol Cell Biol, 2015, 7(2): 143-153.
17. Walters DK, Arendt BK, Jelinek DF. CD147 regulates the expression of MCT1 and lactate export in multiple myeloma cells. Cell Cycle, 2013, 12(19): 3175-3183.
18. Yang JM, O'Neill P, Jin W, et al. Extracellular matrix metallopro-teinase inducer (CD147) confers resistance of breast cancer cells to Anoikis through inhibition of Bim. J Biol Chem, 2006, 281(14): 9719-9727.
19. Wang B, Xu YF, He BS, et al. RNAi-mediated silencing of CD147 inhibits tumor cell proliferation, invasion and increases chemosensi-tivity to cisplatin in SGC7901 cells in vitro. J Exp Clin Cancer Res, 2010, 29: 61.
20. Sato M, Nakai Y, Nakata W, et al. EMMPRIN promotes angiogenesis, proliferation, invasion and resistance to sunitinib in renal cell carcinoma, and its level predicts patient outcome. PLoS One, 2013, 8(9): e74313.
21. Zhao S, Ma W, Zhang M, et al. High expression of CD147 and MMP-9 is correlated with poor prognosis of triple-negative breast cancer (TNBC) patients. Med Oncol, 2013, 30(1): 335.
22. Liu Y, Xin T, Jiang QY, et al. CD147, MMP9 expression and clinical significance of basal-like breast cancer. Med Oncol, 2013, 30(1): 366.
23. Li L, Tang W, Wu X, et al. HAb18G/CD147 promotes pSTAT3-mediated pancreatic cancer development via CD44s. Clin Cancer Res, 2013, 19(24): 6703-6715.
24. Gabison EE, Hoang-Xuan T, Mauviel A, et al. EMMPRIN/CD147, an MMP modulator in cancer, development and tissue repair. Biochimie, 2005, 87(3-4): 361-368.
25. Kaname T, Miyauchi T, Kuwano A, et al. Mapping basigin (BSG), a member of the immunoglobulin superfamily, to 19p13.3. Cytogenet Cell Genet, 1993, 64(3-4): 195-197.
26. Xiong L, Edwards CK 3rd, Zhou L. The biological function and clinical utilization of CD147 in human diseases: a review of the current scientific literature. Int J Mol Sci, 2014, 15(10): 17411-17441.
27. Khayati F, Perez-Cano L, Maouche K, et al. EMMPRIN/CD147 is a novel coreceptor of VEGFR-2 mediating its activation by VEGF. Oncotarget, 2015, 6(12): 9766-9780.
28. Zhao Y, Chen S, Gou WF, et al. The role of EMMPRIN expression in ovarian epithelial carcinomas. Cell Cycle, 2013, 12(17): 2899-2913.
29. Ge H, Yuan W, Liu J, et al. Functional relevance of protein glycosy-lation to the pro-inflammatory effects of extracellular matrix metallo-proteinase inducer (EMMPRIN) on monocytes/macrophages. PLoS One, 2015, 10(2): e0117463.
30. 王艺璇, 高云涛, 崔龙彪, 等.他莫昔芬对糖尿病大鼠心肌CD147糖基化与MMPs的影响.中国应用生理学杂志, 2015, 31(1): 1-5.
31. Sun J, Hemler ME. Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions. Cancer Res, 2001, 61(5): 2276-2281.
32. Nagashima S, Sakurai K, Suzuki S, et al. CD147 expression in non-invasive and invasive breast carcinoma. Gan To Kagaku Ryoho, 2014, 41(10): 1267-1269.
33. Nakamura K, Kodama J, Hongo A, et al. Role of emmprin in endom--etrial cancer. BMC Cancer, 2012, 12: 191.
34. Gao J, Hu Z, Liu J, et al. Expression of CD147 and Lewis y antigen in ovarian cancer and their relationship to drug resistance. Med Oncol, 2014, 31(5): 920.
35. Liu DT. EMMPRIN in gynecologic cancers: pathologic and thera-peutic aspects. Tumour Biol, 2015, 36(7): 4883-4888.
36. Sun X, Liu Y, Li M, et al. Involvement of miR-485-5p in hepatoce-llular carcinoma progression targeting EMMPRIN. Biomed Pharma-cother, 2015, 72: 58-65.
37. Fei F, Li X, Xu L, et al. CD147-CD98hc complex contributes to poor prognosis of non-small cell lung cancer patients through promoting cell proliferation via the PI3K/Akt signaling pathway. Ann Surg Oncol, 2014, 21(13): 4359-4368.
38. Chu D, Zhu S, Li J, et al. CD147 expression in human gastric cancer is associated with tumor recurrence and prognosis. PLoS One, 2014, 9(6): e101027.
39. Abraham D, Zins K, Sioud M, et al. Host CD147 blockade by small interfering RNAs suppresses growth of human colon cancer xenografts. Front Biosci, 2008, 13: 5571-5579.
40. Bilgin Doğru E, Dizdar Y, Aksit E, et al. EMMPRIN and ADAM12 in prostate cancer: preliminary results of a prospective study. Tumour Biol, 2014, 35(11): 11647-11653.
41. 程亮, 徐嘉雯, 何佳佳, 等.膀胱尿路上皮癌分子标记的临床应用进展.中华病理学杂志, 2011, 40(10): 714-717.
42. Kim Y, Choi JW, Lee JH, et al. Expression of lactate/H+ symporters MCT1 and MCT4 and their chaperone CD147 predicts tumor progression in clear cell renal cell carcinoma: immunohistochemical and The Cancer Genome Atlas data analyses. Hum Pathol, 2015, 46(1): 104-112.
43. 万勇, 吴心愿.死亡相关蛋白激酶1和CD147在食管鳞癌中的表达及其临床意义.中华肿瘤杂志, 2012, 34(1): 44-48.
44. Monteiro LS, Delgado ML, Ricardo S, et al. EMMPRIN expression in oral squamous cell carcinomas: correlation with tumor proliferation and patient survival. Biomed Res Int, 2014, 2014: 905680.
45. Andrade AL, Ferreira SJ, Ferreira SM, et al. Immunoexpression of EGFR and EMMPRIN in a series of cases of head and neck squamous cell carcinoma. Pathol Res Pract. 2015, 211(10): 776-781.
46. Yang M, Yuan Y, Zhang H, et al. Prognostic significance of CD147 in patients with glioblastoma. J Neurooncol, 2013, 115(1): 19-26.
47. Hatanaka M, Higashi Y, Fukushige T, et al. Cleaved CD147 shed from the surface of malignant melanoma cells activates MMP2 produced by fibroblasts. Anticancer Res, 2014, 34(12): 7091-7096.
48. Han YH, Gao B, Huang JH, et al. Expression of CD147, PCNA, VEGF, MMPs and their clinical significance in the giant cell tumor of bones. Int J Clin Exp Pathol, 2015, 8(7): 8446-8452.
49. Urbaniak-Kujda D, Kapelko-Slowik K, Prajs I, et al. Increased expre-ssion of metalloproteinase-2 and-9 (MMP-2, MMP-9), tissue inhi-bitor of metalloproteinase-1 and-2 (TIMP-1, TIMP-2), and EMMPRIN (CD147) in multiple myeloma. Hematology, 2016, 21(1): 26-33.
50. Li Y, Xu J, Chen L, et al. HAb18G (CD147), a cancer-associated biomarker and its role in cancer detection. Histopathology, 2009, 54(6): 677-687.
51. Kang MJ, Kim HP, Lee KS, et al. Proteomic analysis reveals that CD147/EMMPRIN confers chemoresistance in cancer stem cell-like cells. Proteomics, 2013, 13(10-11): 1714-1725.
52. Dai L, Guinea MC, Slomiany MG, et al. CD147-dependent hetero-geneity in malignant and chemoresistant properties of cancer cells. Am J Pathol, 2013, 182(2): 577-585.
53. 何慧婵, 韩兆冬, 戴奇山, 等.前列腺癌组织中CD147蛋白的表达及意义.中华医学杂志, 2009, 89(26): 1844-1846.
54. Bhagirath D, Abrol N, Khan R, et al. Expression of CD147, BIGH3 and Stathmin and their potential role as diagnostic marker in patients with urothelial carcinoma of the bladder. Clin Chim Acta, 2012, 413(19-20): 1641-1646.
55. Wu J, Hao ZW, Zhao YX, et al. Full-length soluble CD147 promotes MMP-2 expression and is a potential serological marker in detection of hepatocellular carcinoma. J Transl Med, 2014, 12: 190.
56. Yu XL, Hu T, Du JM, et al. Crystal structure of HAb18G/CD147: implications for immunoglobulin superfamily homophilic adhesion. J Biol Chem, 2008, 283(26): 18056-18065.
57. Cathcart J, Pulkoski-Gross A, Cao J. Targeting matrix metalloprotei-nases in cancer: bringing new life to old ideas. Genes Dis, 2015, 2(1): 26-34.
58. 涂燕, 李振江, 汤爱平, 等.干扰CD147表达对SHI-1细胞体内外增殖及浸润能力的影响及可能机制.中华血液学杂志, 2014, 35(8): 737-742.
59. Taylor PM, Woodfield RJ, Hodgkin MN, et al. Breast cancer cell-derived EMMPRIN stimulates fibroblast MMP2 release through a phospholipase A(2) and 5-lipoxygenase catalyzed pathway. Oncogene, 2002, 21(37): 5765-5772.
60. Chen Y, Gou X, Ke X, et al. Human tumor cells induce angiogenesis through positive feedback between CD147 and insulin-like growth factor-I. PLoS One, 2012, 7(7): e40965.
61. Chen Y, Gou X, Kong DK, et al. EMMPRIN regulates tumor growth and metastasis by recruiting bone marrow-derived cells through paracrine signaling of SDF-1 and VEGF. Oncotarget, 2015, 6(32): 32575-32585.
62. Wang H, Zhuo Y, Hu X, et al. CD147 deficiency blocks IL-8 secretion and inhibits lung cancer-induced osteoclastogenesis. Biochem Biophys Res Commun, 2015, 458(2): 268-273.
63. Quemener C, Gabison EE, Naimi B, et al. Extracellular matrix meta-lloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion. Cancer Res, 2007, 67(1): 9-15.
64. Slomiany MG, Grass GD, Robertson AD, et al. Hyaluronan, CD44, and emmprin regulate lactate efflux and membrane localization of monocarboxylate transporters in human breast carcinoma cells. Cancer Res, 2009, 69(4): 1293-301.
65. Marchiq I, Le Floch R, Roux D, et al. Genetic disruption of lactate/H+ symporters (MCTs) and their subunit CD147/BASIGIN sensitizes glycolytic tumor cells to phenformin. Cancer Res, 2015, 75(1): 171-180.
66. Deora AA, Philp N, Hu J, et al. Mechanisms regulating tissue-specific polarity of monocarboxylate transporters and their chaperone CD147 in kidney and retinal epithelia. Proc Natl Acad Sci U S A, 2005, 102 (45): 16245-16250.
67. Su J, Chen X, Kanekura T. A CD147-targeting siRNA inhibits the proliferation, invasiveness, and VEGF production of human mali-gnant melanoma cells by down-regulating glycolysis. Cancer Lett, 2009, 273(1): 140-147.
68. Gallagher SM, Castorino JJ, Wang D, et al. Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231. Cancer Res, 2007, 67(9): 4182-4189.
69. 周希, 吕洁玉, 龚宝兰.下调CD147通过Bcl-2途径诱导宫颈癌细胞SiHa细胞凋亡的研究.南方医科大学学报, 2010, 30(7): 1695-1698.
70. Gao H, Jiang Q, Han Y, et al. shRNA-mediated EMMPRIN silencing inhibits human leukemic monocyte lymphoma U937 cell proliferation and increases chemosensitivity to adriamycin. Cell Biochem Biophys, 2015, 71(2): 827-835.
71. Gou X, Ru Q, Zhang H, et al. HAb18G/CD147 inhibits starvation-induced autophagy in human hepatoma cell SMMC7721 with an involvement of Beclin 1 down-regulation. Cancer Sci, 2009, 100(5): 837-843.
72. Kuang YH, Chen X, Su J, et al. RNA interference targeting the CD147 induces apoptosis of multi-drug resistant cancer cells related to XIAP depletion. Cancer Lett, 2009, 276(2): 189-195.
73. Tang J, Guo YS, Zhang Y, et al. CD147 induces UPR to inhibit apoptosis and chemosensitivity by increasing the transcription of Bip in hepatocellular carcinoma. Cell Death Differ, 2012, 19(11): 1779-1790.
74. 李江伟, 李道明, 张岚, 等.沉默CD147基因对人甲状腺髓样癌TT细胞相关蛋白表达和生物学特性的影响.中华病理学杂志, 2014, 43(2): 103-108.
75. Hao J, Madigan MC, Khatri A, et al. In vitro and in vivo prostate cancer metastasis and chemoresistance can be modulated by expression of either CD44 or CD147. PLoS One, 2012, 7(8): e40716.
76. Ozler A, Evsen MS, Turgut A, et al. CD147 expression in uterine smooth muscle tumors, and its potential role as a diagnostic and prognostic marker in patients with leiomyosarcoma. J Exp Ther Oncol, 2014, 10(4): 325-330.
77. Toole BP, Slomiany MG. Hyaluronan, CD44 and Emmprin: partners in cancer cell chemoresistance. Drug Resist Updat, 2008, 11(3): 110-121.
78. Hao J, Chen H, Madigan MC, et al. Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression. Br J Cancer, 2010, 103(7): 1008-1018.
79. 胡芸, 吴宜林. CD147单克隆抗体对HCE1多细胞球体紫杉醇耐药的影响.中南大学学报医学版, 2011, 36(3): 192-202.
80. Pan Y, He B, Song G, et al. CD147 silencing via RNA interference reduces tumor cell invasion, metastasis and increases chemosensiti-vity in pancreatic cancer cells. Oncol Rep, 2012, 27(6): 2003-2009.
81. Zhou S, Liao L, Chen C, et al. CD147 mediates chemoresistance in breast cancer via ABCG2 by affecting its cellular localization and dimerization. Cancer Lett, 2013, 337(2): 285-292.
82. Li QQ, Wang WJ, Xu JD, et al. Involvement of CD147 in regulation of multidrug resistance to P-gp substrate drugs and in vitro invasion in breast cancer cells. Cancer Sci, 2007, 98(7): 1064-1069.
83. Zhu S, Chu D, Zhang Y, et al. EMMPRIN/CD147 expression is associated with disease-free survival of patients with colorectal cancer. Med Oncol, 2013, 30(1): 369.
84. Boye K, Nesland JM, Sandstad B, et al. EMMPRIN is associated with S100A4 and predicts patient outcome in colorectal cancer. Br J Cancer, 2012, 107(4): 667-674.
85. Xu Q, Ying M, Chen G, et al. ADAM17 is associated with EMMPRIN and predicts poor prognosis in patients with uterine cervical carci-noma. Tumour Biol, 2014, 35(8): 7575-7586.
86. Choi JW, Kim Y, Lee JH, et al. Prognostic significance of lactate/proton symporters MCT1, MCT4, and their chaperone CD147 expressions in urothelial carcinoma of the bladder. Urology, 2014, 84(1): 245. e9-e15.
87. Zhu S, Li Y, Mi L, et al. Clinical impact of HAb18G/CD147 expres-sion in esophageal squamous cell carcinoma. Dig Dis Sci, 2011, 56 (12): 3569-3576.
88. Xu XY, Lin N, Li YM, et al. Expression of HAb18G/CD147 and its localization correlate with the progression and poor prognosis of non-small cell lung cancer. Pathol Res Pract, 2013, 209(6): 345-352.
89. Rabien A, Stephan C, Kilic E, et al. Renal cell neoplasias: reversion-inducing cysteine-rich protein with Kazal motifs discriminates tumor subtypes, while extracellular matrix metalloproteinase inducer indicates prognosis. J Transl Med, 2013, 11: 258.
90. Gou X, Chen H, Jin F, et al. Expressions of CD147, MMP-2 and MMP-9 in laryngeal carcinoma and its correlation with poor prognosis. Pathol Oncol Res, 2014, 20(2): 475-481.
91. Futamura N, Nishida Y, Urakawa H, et al. EMMPRIN co-expressed with matrix metalloproteinases predicts poor prognosis in patients with osteosarcoma. Tumour Biol, 2014, 35(6): 5159-5165.
92. Bi XC, Liu JM, He HC, et al. Extracellular matrix metalloproteinase inducer: a novel poor prognostic marker for human seminomas. Clin Transl Oncol, 2012, 14(3): 190-196.
93. Zhong X, Li M, Nie B, et al. Overexpressions of RACK1 and CD147 associated with poor prognosis in stage T1 pulmonary adenocar-cinoma. Ann Surg Oncol, 2013, 20(3): 1044-1052.
94. Sugyo A, Tsuji AB, Sudo H, et al. Evaluation of 89Zr-labeled human anti-CD147 monoclonal antibody as a positron emission tomography probe in a mouse model of pancreatic cancer. PLoS One, 2013, 8(4): e61230.
95. Grupp K, Hohne TS, Prien K, et al. Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatec-tomy. Exp Mol Pathol, 2013, 95(2): 227-234.
96. Bi XC, Liu JM, Zheng XG, et al. Over-expression of extracellular matrix metalloproteinase inducer in prostate cancer is associated with high risk of prostate-specific antigen relapse after radical prostatectomy. Clin Invest Med, 2011, 34(6): E358.
97. Niu H, Wang R, Cheng J, et al. Treatment of 131I-labeled anti-CD147 monoclonal antibody in VX2 carcinoma-induced liver tumors. Oncol Rep, 2013, 30(1): 246-252.
98. Bian H, Zheng JS, Nan G, et al. Randomized trial of 131I metuximab in treatment of hepatocellular carcinoma after percutaneous radio-frequency ablation. J Natl Cancer Inst, 2014, 106(9). pii: dju239.

Previous Article
Application of Dual-Energy CT Scanning Technology in The Liver
Next Article
空肠胃逆行性套叠1例报道

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Biological Function of EMMPRIN in Tumor Progression

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content